Deerfield Management Company, L.P. (Series C) Dyne Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 812,408 shares of DYN stock, worth $8.08 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
812,408
Previous 435,653
86.48%
Holding current value
$8.08 Million
Previous $10.3 Million
17.21%
% of portfolio
0.22%
Previous 0.25%
Shares
8 transactions
Others Institutions Holding DYN
# of Institutions
217Shares Held
116MCall Options Held
322KPut Options Held
66.2K-
Janus Henderson Group PLC London, X010.4MShares$103 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$96.7 Million2.11% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$90.8 Million27.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.41MShares$73.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$73.5 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $515M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...